Community Health Systems Inc.
CYHBusiness Overview
source: coverage-next-full ticker: CYH step: "01" title: Business Overview — Company Description, Segments, Operations created: 2026-05-29
Step 01 — Business Overview: Community Health Systems
Company Summary
Community Health Systems, Inc. (NYSE: CYH) is one of the largest publicly traded for-profit hospital companies in the United States. The company owns, leases, and operates general acute care hospitals primarily in non-urban and mid-sized markets where it is often the sole or dominant community hospital provider. As of late 2024, CYH operates approximately 70 hospitals across roughly 15 states, down from a peak of approximately 200+ hospitals when the company was at its largest (following the 2014 acquisition of Health Management Associates).
The company is headquartered in Franklin, Tennessee, and operates through its primary operating subsidiary, Community Health Systems Professional Services Corporation (CHSPSC, LLC).
Operating Segments
CYH operates as a single reportable segment: hospital operations. All financial reporting is on a consolidated basis without geographic or product segment breakdowns at the reporting level.
However, operationally the portfolio can be characterized along these dimensions:
By Market Type
- Non-urban / Rural Markets: Hospitals in smaller communities (typically population 20,000–200,000) where CYH is often the primary or only hospital
- Mid-Sized Markets: Larger community hospitals serving suburban markets adjacent to major metro areas
- Urban/Tertiary Adjacent: A smaller subset of hospitals in or near larger metro markets
By Service Line
- Inpatient Acute Care: Core business — medical/surgical, ICU, emergency, obstetrics
- Emergency Services: Emergency department volumes are the primary patient acquisition channel
- Outpatient Services: Growing contribution — ambulatory surgery, imaging, lab, physician clinics
- Employed Physician Practices: CYH employs thousands of physicians across primary care and specialty practices to maintain referral networks and support hospital volumes
- Behavioral Health: Select facilities include psychiatric/behavioral health units
By Geography (as of 2024)
Key states include Alabama, Florida, Indiana, Kansas, Mississippi, Nevada, New Jersey, New Mexico, Ohio, Pennsylvania, Tennessee, Texas, Utah, Virginia, and West Virginia. Hospital concentration in the South and Midwest reflects the original strategy of targeting markets with limited competition.
Business Model
Revenue Generation: CYH generates revenue through:
- Providing inpatient hospital services (billed per admission or per DRG under Medicare)
- Providing outpatient services (billed per procedure or per visit)
- Emergency department services (high-volume, broad payor mix)
- Employed physician billings (largely professional services billed separately)
Payor Mix (approximate, 2023–2024):
- Medicare: ~25–28% of net patient revenue
- Medicaid: ~18–22% of net patient revenue
- Commercial/Managed Care: ~35–40% of net patient revenue
- Self-pay/Uninsured: ~5–8% of net patient revenue (before charity care adjustments)
The relatively high Medicaid exposure (versus peers like HCA which skews toward commercial) is a defining characteristic of CYH's community/non-urban market focus.
Strategic Context
Divestiture Program (Ongoing Since ~2016)
Following the heavily leveraged 2014 acquisition of Health Management Associates (HMA) for ~$7.6B, CYH has been in a prolonged portfolio rationalization mode. The strategy involves:
- Selling hospitals in non-core, underperforming, or strategically redundant markets
- Using divestiture proceeds to reduce debt
- Retaining and investing in "core" markets with stronger competitive positioning
Hospital Count Trajectory:
- 2014 peak: ~200 hospitals (post-HMA)
- 2016: ~158 hospitals
- 2018: ~120 hospitals
- 2020: ~100 hospitals
- 2022: ~80 hospitals
- 2024: ~70 hospitals
Operational Improvement Focus
Current management priorities include:
- Revenue cycle management (reduce bad debt, improve collections efficiency)
- Clinical quality improvements (reduce preventable readmissions, improve length of stay)
- Physician recruitment (attract/retain specialists to maintain volumes)
- Outpatient growth (expand ambulatory surgery centers, urgent care)
- Labor cost management (agency nurse reduction, workforce productivity)
Ownership & Corporate Structure
- Public Float: CYH common stock trades on NYSE
- Major Shareholders: Institutional investors (Vanguard, BlackRock, hedge funds active in distressed healthcare)
- Operating Subsidiary: CHSPSC, LLC issues the debt (parent is the guarantor)
- No Material Non-Controlling Interests: Most hospitals are 100% owned; some joint ventures with non-profit health systems exist
Employees
Approximately 55,000–65,000 employees as of 2023–2024 (down from 120,000+ at peak), reflecting the portfolio reduction. Workforce includes employed physicians, nurses, allied health, and administrative staff.
Financial Snapshot
source: coverage-next-full ticker: CYH step: "04" title: Financial Snapshot — 3-Year P&L Summary created: 2026-05-29
Step 04 — Financial Snapshot: CYH
3-Year Income Statement Summary (Continuing Operations)
All figures in millions USD. FY data from 10-K filings; 2024 estimated from 9M actuals and guidance.
| Metric | FY 2022 | FY 2023 | FY 2024E |
|---|---|---|---|
| Net Operating Revenue | $12,497 | $12,273 | $12,600–12,900 |
| Operating Costs & Expenses | |||
| Salaries & Benefits | ~$5,400 | ~$5,200 | ~$5,300 |
| Supplies | ~$1,500 | ~$1,450 | ~$1,500 |
| Other Operating Expenses | ~$3,200 | ~$3,100 | ~$3,150 |
| Depreciation & Amortization | ~$650 | ~$600 | ~$580 |
| Total Operating Costs | ~$10,750 | ~$10,350 | ~$10,530 |
| Operating Income (EBIT) | ~$1,050 | ~$1,050 | ~$1,100 |
| Interest Expense, net | ~$(750) | ~$(770) | ~$(760) |
| Other Income / (Expense) | Variable | Variable | Variable |
| Income Before Taxes | ~$300 | ~$280 | ~$340 |
| Income Tax Expense | ~$(85) | ~$(75) | ~$(90) |
| Net Income from Continuing Ops | ~$215 | ~$205 | ~$250 |
| Discontinued Operations, net | Variable | Variable | ~$(50–100) |
| Net Income (Total) | Variable | ~$100–150 | Variable |
| Net Income Attributable to CYH | ~$60–90 | ~$80–120 | ~$100–150 |
Non-GAAP Metrics (Key Reported Figures)
| Metric | FY 2022 | FY 2023 | FY 2024E |
|---|---|---|---|
| Adjusted EBITDA | ~$1,480 | ~$1,500 | ~$1,550–1,600 |
| Adjusted EBITDA Margin | ~11.8% | ~12.2% | ~12.3–12.5% |
| Free Cash Flow (est.) | ~$100–200 | ~$150–250 | ~$200–300 |
Note: Adjusted EBITDA excludes stock-based compensation, impairment charges, gains/losses on divestitures, and certain non-recurring items. Management guidance typically focuses on Adjusted EBITDA as the primary profitability metric.
Per Share Data
| Metric | FY 2022 | FY 2023 | FY 2024E |
|---|---|---|---|
| Diluted Shares Outstanding (M) | ~135–140 | ~137–142 | ~137–142 |
| EPS (Continuing Ops, GAAP) | ~$1.50–1.60 | ~$1.45–1.55 | ~$1.75–2.00 |
| EPS (Total, GAAP) | Variable | ~$0.70–1.00 | Variable |
| Adjusted EPS (Non-GAAP) | Variable | ~$3.00–4.00 | ~$3.50–4.50 |
Margin Analysis
| Margin | FY 2022 | FY 2023 | FY 2024E | vs. HCA Benchmark |
|---|---|---|---|---|
| Gross Margin (Revenue – Direct Costs) | N/A (single segment, not reported separately) | — | — | — |
| EBITDA Margin | ~18.4% | ~18.7% | ~18.8% | HCA ~22%+ |
| Adjusted EBITDA Margin | ~11.8% | ~12.2% | ~12.3% | HCA ~20%+ |
| Operating Margin (EBIT/Revenue) | ~8.4% | ~8.5% | ~8.7% | HCA ~14%+ |
| Net Margin (Total) | ~0.5–0.7% | ~0.6–1.0% | ~0.8–1.2% | HCA ~9%+ |
Note: CYH's significantly lower net margin vs. HCA reflects the massive interest burden (~$750–770M/year) on its ~$12B+ debt load. Pre-interest operating margins are closer to peer range.
Revenue Bridge: Key Growth Drivers
Organic Growth (Same-Store)
- Admission volume growth: +1–3% annually (modest; demographics + market share)
- Rate/mix improvement: +3–5% (Medicare rate updates + commercial rate escalators)
- Combined same-store revenue growth: ~4–7% annually at established facilities
Portfolio Offset
- Hospital divestitures offset organic growth at the consolidated level
- 2022–2024: Net revenue roughly flat to slight growth despite organic underlying improvement
Cost Structure Analysis
| Cost Category | % of Revenue | Commentary |
|---|---|---|
| Salaries & Benefits | ~42–44% | Largest cost; direct nursing/physician labor + admin |
| Supplies (Medical/Pharma) | ~11–12% | Drug, implant, device costs |
| Other Operating | ~25–27% | Facilities, utilities, IT, insurance, contracted services |
| Depreciation | ~4.8–5.2% | Equipment, building |
| Total OpEx | ~84–86% | Leaves ~14–16% EBITDA |
| Interest Expense | ~6.0–6.5% | Critical constraint; limits bottom-line earnings |
Labor Cost Normalization: Post-COVID, agency/traveling nurse costs peaked in 2022 adding ~$200–400M in incremental labor cost vs. pre-pandemic norms. Gradual normalization was underway in 2023–2024 as CYH rebuilt permanent staffing ratios.
Guidance (FY 2024)
Management FY 2024 guidance (as communicated through Q3 2024 earnings):
- Net Revenue: $12.5–13.0B
- Adjusted EBITDA: $1.52–1.58B
- Capital Expenditures: ~$400–500M
These targets reflect same-store growth partially offset by planned divestitures and the expectation of continued labor cost normalization.
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $CYH.